Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody with a domain that binds to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. Show more

Location: 116 Huntington Avenue, Boston, MA, 02116, United States | Website: https://www.bicara.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

596.1M

52 Wk Range

$7.80 - $28.09

Previous Close

$10.93

Open

$10.94

Volume

274,533

Day Range

$10.94 - $11.41

Enterprise Value

45.17M

Cash

462.1M

Avg Qtr Burn

-22.07M

Insider Ownership

11.65%

Institutional Own.

89.28%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.